Does Alaska Medicaid Cover Wegovy or Zepbound? Heart, Liver and Sleep Apnea Rules

No GLP-1 is covered for weight loss in Alaska Medicaid, Wegovy and Zepbound included, because a state regulation bars payment for drugs that treat obesity.^[6] As of November 2026, its own criteria still approve Wegovy with prior authorization for adults with heart disease or the liver disease MASH from a BMI of 25, and Zepbound for moderate to severe sleep apnea from a BMI of 30.^[1][2]

Can Alaska Medicaid pay for a GLP-1 to lose weight?

No. Two regulations close that door. One says the department will not pay for “a drug used to treat infertility, obesity, or baldness,” and another excludes nonsurgical weight reduction programs and products.^[6][7] Both GLP-1 criteria documents repeat the point as a denial reason: a prescription “for purposes of weight control” is refused under those two rules.^[1][2]

Federal law makes weight-loss drugs one of the few classes a state may exclude from Medicaid, so Alaska is within its rights.^[9] Our guide to why Medicaid treats Ozempic and Wegovy differently explains that option. What surprises people is how much remains once weight loss is off the table.

Which GLP-1 uses does Alaska Medicaid cover?

Neither Wegovy nor Zepbound appears on the November 2026 drug list, so every request for either one goes through prior authorization.^[5] The criteria then decide the outcome, use by use.

Every one of these approvals also carries a promise from the prescriber: once the covered condition is under control, the dose will not be raised just to produce more weight loss.^[1][2] The same documents list automatic denials: medullary thyroid cancer in the patient or a relative, MEN 2, severe gastroparesis, or use together with another GLP-1 or GIP drug.^[1][2]

Will Alaska Medicaid cover Wegovy after a heart attack or stroke?

Yes, with a low weight bar. The request needs a BMI of 25 or more and a documented diagnosis from a short list: a prior heart attack, a prior ischemic or bleeding stroke, chronic ischemic heart disease, peripheral artery disease or atherosclerosis.^[1] Both the injection and the Wegovy tablets qualify.^[1]

The criteria say nothing about a minimum age beyond the label’s, a diabetes exclusion, a cardiologist, or a list of heart drugs the patient must already take.^[1] The label itself covers adults with established heart disease and either obesity or overweight, so a BMI of 25 to 27 sits at the low edge of that use, and a prescriber should document the heart diagnosis clearly.^[12]

Does Alaska Medicaid cover Wegovy for fatty liver disease?

It covers the Wegovy injection, not the tablets, for MASH with moderate to advanced fibrosis at stages F2 to F3, again from a BMI of 25.^[1] The criteria ask for a documented diagnosis and do not name a test, so a biopsy report or a liver stiffness result gives the strongest file. The FDA approved this use on an accelerated basis, pending a confirmatory trial.^[12] Our page on GLP-1s and MASH covers the evidence.

What does Alaska require for Zepbound and sleep apnea?

A BMI of 30 or more and moderate to severe sleep apnea confirmed by a sleep study, with the apnea-hypopnea index defined as “greater than 15 events per hour.”^[2] Read that number closely. The Zepbound trials counted an AHI of 15 as moderate sleep apnea, but a result of exactly 15 does not clear Alaska’s wording, so check the report before filing.^[11] The criteria do not require a CPAP trial or a sleep specialist.^[2]

The Zepbound label covers sleep apnea only in adults who have obesity, which is why the BMI line sits at 30 here.^[11] Our guide to Zepbound for sleep apnea covers the trial results.

What about Ozempic and Mounjaro for diabetes?

Ozempic, including the new Ozempic tablets, is a preferred drug, along with Rybelsus, Trulicity and Victoza.^[5] Preferred still means criteria. A qualifying diagnosis code sent with the pharmacy claim can carry the request; otherwise the prescriber documents type 2 diabetes with an A1C above 7% in the last 60 days, heart disease or a qualifying kidney finding, and the criteria also call for a current diabetes care plan and three months of metformin at the highest tolerated dose.^[1]

Mounjaro is non-preferred.^[5] On top of the diabetes steps, it needs a three-month trial of two preferred GLP-1s at their highest tolerated doses that did not work or caused side effects bad enough to stop.^[2]

How long does an approval last in Alaska?

The first approval runs up to three months and a renewal up to 12.^[1][2] That short first window matters because these drugs start low and step up each month. Alaska’s approvals are tied to a specific strength, and a change in strength “may require a new prior authorization,” so ask the prescriber to plan the dose steps with the pharmacy before the first fill.^[1][2] The limit is four pens a month for either drug, or 34 Wegovy tablets per 34 days.^[1][2]

Requests go on the General Prior Authorization Form with the criteria attached, faxed to Prime Therapeutics at (888) 603-7696; the phone line is (800) 331-4475.^[3][4]

Can a teenager on Alaska Medicaid get Wegovy?

Not for obesity under the written criteria. The Wegovy label includes obesity from age 12, but Alaska marks that use non-covered.^[1][12] Federal child-health rules do require states to provide necessary treatment for people under 21 “whether or not such services are covered under the State plan,” so a family can ask for a medical necessity review.^[10] Alaska’s criteria do not describe one.

How do you appeal a denial in Alaska?

Act fast. Alaska’s rule gives 30 days from the date of the notice to request a hearing in writing, and a late request is accepted only if a judge finds it could not have been filed in time.^[8] An appeal has the most to work with when the dispute is about evidence for a covered use, such as a sleep study that reads 16 events per hour or records of a past stroke. It has little to work with when the only diagnosis is obesity.^[6]

Our walkthrough of prior authorization and appeals covers what to put in the file, and the Alaska state page summarizes the Medicaid facts.

What are the options if Alaska Medicaid says no?

Paying cash is the main one. Lilly’s savings card terms exclude anyone enrolled in Medicaid, so a copay card will not help.^[13] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses through Novo Nordisk, and $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time for Lilly’s Zepbound.^[13][14] Check each offer’s rules on government coverage before you sign up. Our list of the cheapest GLP-1 routes without insurance compares them.